Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000008) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
Affibody Tifalibep
|
|||||
| Synonyms |
ABY-039; ABY039
|
|||||
| Molecular Weight | 19 kDa | |||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I; Discontinued | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS004 | [1] | ||||
| Scaffold Name | Affibody | |||||
| Scaffold Class | Non-Antibody | |||||
| Fold Type | Three Alpha-Helices | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| Fc receptor | Inhibitor | Antibody (IgG) mediated autoimmune | N.A. | Affibody AB | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT03502954 | Click to show the Detail | |||||
| Indication | Healthy Subjects | |||||
| Phase | Phase I | |||||
| Title | A Phase I, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects | |||||
| Status | Terminated (Halted prematurely) | |||||
| Sponsor | Affibody | |||||